Emergency surgery in the era of molecular treatment of solid tumours.
In the advancing era of molecular therapy of solid tumours, emergency treatment of complications, such as bowel perforation, haemorrhage, and tumour rupture, is likely to evolve into one of the main challenges of surgical oncology. These complications might be caused by disease progression from resistance to therapy, side-effects of therapy on normal vasculature, and therapeutic induction of excessively responding tumours. This Review outlines the probability and management of emergency operations during molecularly targeted therapy of solid tumours. Special attention is given to advanced gastrointestinal stromal tumours and colorectal cancer, and therapy with imatinib, sunitinib, and bevacizumab.
Rutkowski
Piotr
P
Department of Soft Tissue/Bone Sarcoma and Melanoma, M Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland. rutkowskip@coi.waw.pl
Ruka
Włodzimierz
W
D000970:Antineoplastic Agents / Q000009:adverse effects*; D016503:Drug Delivery Systems; D004630:Emergencies; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000601:surgery*
D000970:Antineoplastic Agents